CAMK2G and cardiac hypertrophy: It was reported that H19 regulates cardiac hypertrophy through miR-675 and genetic variation at this lncRNA is associated with the risk of HCM [12,19], that MIAT perform like a miR-150 molecular sponge [13], MHRT antagonizes the role of Brg1 in cardiac hypertrophy [9], PVT1 modulates the pathological cardiac hypertrophy via miR-196b [18] and TINCR regulates cardiac hypertrophy through the epigenetic silencing of CaMKII [16];however, only a limited number of lncRNAs have been identified as regulators of cardiac hypertrophy.